Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 1:34 AM
Ignite Modification Date: 2025-12-25 @ 1:34 AM
NCT ID: NCT03658694
Eligibility Criteria: Inclusion Criteria: 1. Female patients with diagnosis fibromyalgia according to the ACR 2016 criteria (patient satisfies modified 2016 fibromyalgia criteria if the following 3 conditions are met: 1) widespread pain index (WPI) ≥ 7 and symptom severity scale (SSS) score 5 OR WPI of 4-6 and SSS score ≥ 9. 2) Generalized pain, defined as pain in at least 4 of 5 regions, must be present. Jaw, chest, and abdominal pain are not included in generalized pain definition. 3) Symptoms have been generally present for at least 3 months. 4) A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses). 2. Age ≥18 years; 3. Be able to understand study protocol and give signed, written informed consent 4. Not under opioids 5. VAS score ≥ 40/100 mm; Exclusion Criteria: 1. Known abuse of alcohol or illicit drugs 2. Known psychiatric conditions 3. Contraindications to rTMS (42) (Head trauma or concussion, metal implants in the skull, pregnancy, cardiac pacemaker, medication infusion devices, previous troubles with TMS or MRI); 4. Not being under chronic contraceptive use (intrauterine dispositive or oral contraceptive) 5. Other medical conditions demand hospitalization; 6. Participation in other clinical studies at the same time
Healthy Volunteers: False
Sex: FEMALE
Minimum Age: 18 Years
Maximum Age: 80 Years
Study: NCT03658694
Study Brief:
Protocol Section: NCT03658694